SYRE
Income statement / Annual
Last year (2024), Spyre Therapeutics, Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Spyre Therapeutics, Inc.'s net income was -$208.02 M.
See Spyre Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$0.00 |
$886,000.00 |
$2.33 M |
$18.74 M |
$0.00 |
$0.00 |
$3.89 M |
$5.21 M |
$4.63 M |
$6.09 M |
| Cost of Revenue |
$0.00
|
$964,000.00
|
$1.96 M
|
$2.00 M
|
$1.62 M
|
$901,000.00
|
$0.00
|
$0.00
|
$0.00
|
$89,000.00
|
| Gross Profit |
$0.00
|
-$78,000.00
|
$365,000.00
|
$16.74 M
|
-$1.62 M
|
-$901,000.00
|
$3.89 M
|
$5.21 M
|
$4.63 M
|
$6.00 M
|
| Gross Profit Ratio |
0
|
-0.09
|
0.16
|
0.89
|
0
|
0
|
1
|
1
|
1
|
0.99
|
| Research and Development Expenses |
$162.79 M
|
$89.50 M
|
$58.58 M
|
$57.07 M
|
$59.64 M
|
$64.60 M
|
$36.72 M
|
$22.82 M
|
$18.14 M
|
$11.45 M
|
| General & Administrative Expenses |
$45.78 M
|
$39.95 M
|
$28.53 M
|
$27.32 M
|
$21.84 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$5.95 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$45.78 M
|
$39.95 M
|
$28.53 M
|
$27.32 M
|
$21.84 M
|
$14.83 M
|
$12.34 M
|
$9.82 M
|
$8.26 M
|
$5.95 M
|
| Other Expenses |
$0.00
|
$113.74 M
|
-$7,000.00
|
-$122,000.00
|
-$5,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$208.57 M
|
$243.19 M
|
$87.11 M
|
$84.39 M
|
$81.48 M
|
$79.43 M
|
$49.06 M
|
$32.63 M
|
$26.40 M
|
$17.40 M
|
| Cost And Expenses |
$0.00
|
$243.19 M
|
$87.11 M
|
$84.39 M
|
$81.48 M
|
$80.33 M
|
$49.35 M
|
$32.88 M
|
$26.53 M
|
$17.40 M
|
| Interest Income |
$21.31 M
|
$6.15 M
|
$837,000.00
|
$111,000.00
|
$593,000.00
|
$2.14 M
|
$1.17 M
|
$482,000.00
|
$244,000.00
|
$22,000.00
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$0.00
|
$964,000.00
|
$1.96 M
|
$2.00 M
|
$1.62 M
|
$901,000.00
|
$293,000.00
|
$249,000.00
|
$132,000.00
|
$89,000.00
|
| EBITDA |
-$207.97 M |
-$127.82 M |
-$83.21 M |
-$63.66 M |
-$79.27 M |
-$77.35 M |
-$45.17 M |
-$27.43 M |
-$21.77 M |
-$11.23 M |
| EBITDA Ratio |
0
|
-144.27
|
-35.73
|
-3.4
|
0
|
0
|
-11.62
|
-5.27
|
-4.7
|
-1.84
|
| Operating Income Ratio |
0
|
-273.48
|
-36.4
|
-3.5
|
0
|
0
|
-11.69
|
-5.32
|
-4.73
|
-1.86
|
| Total Other Income/Expenses Net |
$599,000.00
|
-$96.51 M
|
$830,000.00
|
-$11,000.00
|
$588,000.00
|
$2.08 M
|
$1.12 M
|
$440,000.00
|
$208,000.00
|
$20,000.00
|
| Income Before Tax |
-$207.97 M
|
-$338.82 M
|
-$83.95 M
|
-$65.66 M
|
-$80.89 M
|
-$78.25 M
|
-$44.35 M
|
-$27.24 M
|
-$21.70 M
|
-$11.30 M
|
| Income Before Tax Ratio |
0
|
-382.41
|
-36.05
|
-3.5
|
0
|
0
|
-11.41
|
-5.23
|
-4.69
|
-1.86
|
| Income Tax Expense |
$51,000.00
|
-$26,000.00
|
-$136,000.00
|
$141,000.00
|
-$593,000.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$208.02 M
|
-$338.79 M
|
-$83.82 M
|
-$65.80 M
|
-$80.89 M
|
-$78.25 M
|
-$44.35 M
|
-$27.24 M
|
-$21.70 M
|
-$11.30 M
|
| Net Income Ratio |
0
|
-382.38
|
-35.99
|
-3.51
|
0
|
0
|
-11.41
|
-5.23
|
-4.69
|
-1.86
|
| EPS |
-0.56 |
-46.15 |
-24.86 |
-25.02 |
-37.89 |
-61.23 |
-53.25 |
-45.01 |
-55.4 |
-25.2 |
| EPS Diluted |
-0.56 |
-46.15 |
-24.86 |
-25.02 |
-37.89 |
-61.23 |
-53.25 |
-45.01 |
-55.4 |
-25.2 |
| Weighted Average Shares Out |
$374.39 M
|
$7.34 M
|
$3.37 M
|
$2.63 M
|
$2.13 M
|
$1.28 M
|
$832,902.00
|
$605,127.00
|
$391,669.00
|
$457,193.00
|
| Weighted Average Shares Out Diluted |
$374.39 M
|
$7.34 M
|
$3.37 M
|
$2.63 M
|
$2.13 M
|
$1.28 M
|
$832,902.00
|
$605,127.00
|
$391,669.00
|
$457,193.00
|
| Link |
|
|
|
|
|
|
|
|
|
|
